In this presentation, Kathleen Noack, Vice President of Business Development Tides for Jiuzhou Pharmaceutical, dives into the R&D and GMP facilities at Jiuzhou. The presentation began by focusing on Jiuzhou's mission to serve life and guard health, highlighting the company's commitment to both blockbuster and orphan drugs.
Jiuzhou Pharmaceutical, headquartered in Zhejiang, China, employs over 5000 people and operates in seven R&D facilities, including locations in the US, Japan, and Germany. The company manages ten manufacturing facilities and has commercialised 24 products, serving customers in more than 90 countries. Noack emphasised Jiuzhou's expertise in peptides, with key production sites in Suzhou, Hangzhou, and Taizhou.
Founded in 1973, Jiuzhou established its CDMO division in 2008 and went public in 2014. The company reported a revenue of $815 million in 2023 and successfully undertook over 1000 projects, impacting more than 80 million patients worldwide. Jiuzhou provides comprehensive services, including manufacturing, analytical support, process development, and registration assistance.
Noack highlighted Jiuzhou's impressive KPI of 98% on-time delivery and its collaboration with major pharmaceutical companies like Novartis and Roche. The company's R&D investment was substantial, with 6% of revenue dedicated to innovation and 900 employees working in this sector. Jiuzhou's peptide capabilities included SPPS, LPPS, and hybrid synthesis approaches, with advanced purification and high potent compound capacities.
Noack also discussed Jiuzhou's environmental commitment, mentioning the gold award from EcoVadis for its environmental health and safety practices. The company’s sustainable efforts sport solvent recovery systems, solid incineration systems, and robust quality management, evidenced by multiple successful FDA inspections.
In conclusion, Noack’s presentation provided a comprehensive overview of Jiuzhou Pharmaceutical's capabilities, achievements, and commitment to quality and innovation, positioning the company as a trusted partner in the pharmaceutical industry.
